ACEA 1021, a glycine site antagonist with minor psychotomimetic and amnestic effects in rats

European Journal of Pharmacology

Volumn 331, Issue 2-3, 1997, Pages 109-116

  Kretschmer, Beate D ^a   Kratzer, Ulrich ^a   Breithecker, Katharina ^a   Koch, Michael ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Animal Physiology   (Germany)

Author keywords

ACEA 1021; Amnesia; Glutamate; Glycine; Psychotomimetic; Side effcts

Indexed keywords

6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CYCLOSERINE; GLYCINE RECEPTOR; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PSYCHEDELIC AGENT;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CATALEPSY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG ACTIVITY; LOCOMOTION; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; STARTLE REFLEX; STEREOTYPY;

AMNESIA; ANIMALS; ANTIMETABOLITES; BEHAVIOR, ANIMAL; CATALEPSY; CYCLOSERINE; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; HALLUCINOGENS; MALE; MAZE LEARNING; MOTOR ACTIVITY; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLYCINE; STARTLE REACTION;

EID: 0030815925     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01047-9     Document Type: Article

References (55)

1. Albers, G.W., Atkinso, R.P., Kelly, R.E., Rosenbaum, D.M., 1995. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 26, 254-258.
2. Balster, R.L., Mansbach, R.S., Shelton, K.L., Nicholson, K.L., Grech, D.M., Wiley, J.L., Li, H., Weber, E., 1995. Behavioural pharmacology of two novel substituted quinoxalidone glutamate antagonists. Behav. Pharmacol. 6, 577-590.
3. Berger, P., Farrel, K., Sharp, P., Skolnick, P., 1994. Drugs acting at the strychnine-insensitive glycine receptor do not induce HSP-70 protein in the cingulate cortex. Neurosci. Lett. 168, 147-150.
4. Bigge, C.F., 1993. Structural requirements for the development of potent N-methyl-D-aspartic acid (NMDA) receptor antagonists. Biochem. Pharmacol. 45, 1547-1561.
5. Bischoff, C., Tiedtke, P.I., 1992. Competitive and non-competitive NMDA receptor antagonists in spatial learning tasks. Eur. J. Pharmacol. 213, 269-273.
6. Bristow, L.J., Landon, L., Saywell, K.L., Tricklebank, M.D., 1995. The glycine/NMDA receptor antagonist, L-701,324 reverses isolation-induced deficits in prepulse inhibition in the rat. Psychopharmacology 118, 230-232.
7. Bubser, M., Keseberg, U., Notz, P.K., Schmidt, W.J., 1992. Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats. Eur. J. Pharmacol. 229, 75-82.
8. Bubser, M., Zadow, B., Rückert, N.G.H., Keseberg, U., Kronthaler, U., Schmidt, W.J., 1994. Behavioural action of the non-competitive NMDA antagonists dextrorphan and ADCI in relation to dopaminergic mechanisms. Behav. Pharmacol. 5 (S1), 177.
9. Chiamulera, C., Costa, S., Reggiani, A., 1990. Effect of NMDA- and strychine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning. Psychopharmacology 102, 551-552.
10. Clineschmidt, B.V., Martin, G.E., Bunting, P.R., 1982. Anticonvulsant activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev. Res. 2, 123-134.
11. Danysz, W., Essman, U., Bresink, I., Wilke, R., 1994. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol. Biochem. Behav. 48, 111-118.
12. Danysz, W., Parsons, C.G., Bresink, I., Quack, G., 1995. Glutamate in CNS disorders: A revived target for drug development?. DN&P 8, 261-277.
13. Danysz, W., Wroblewski, J.T., 1989. Amnesic properties of glutamate receptor antagonists. Neurosci. Res. Commun. 5, 9-18.
14. Danysz, W., Wroblewski, J.T., Costa, E., 1988. Learning impairment in rats by N-methyl-D-aspartate receptor antagonists. Neuropharmacology 27, 658-666.
15. Dunn, R.W., Flanagan, D.M., Martin, L.L., Kerman, L.L., Woods, A.T., Camacho, F., Wilmot, C.A., Cornfeldt, M.L., Effland, R.C., Wood, P.L., Corbett, R., 1992. Stereoselective R-(+) enantiomer of HA-966 displays anxiolytic effects in rodents. Eur. J. Pharmacol. 214, 207-214.
16. Foster, A.C., Willis, C.L., Tridgett, R., 1990. Protection against N-methyl-D-aspartate receptor-mediated neuronal degeneration in rat brain by 7-chlorokynurenate and 3-amino-1-hydroxypyrrolid-2-one, antagonists at the allosteric site for glycine. Eur. J. Neurosci. 2, 270-277.
17. Hargreaves, R.J., Rigby, M., Smith, D., Hill, R.G., 1993. Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology. Br. J. Pharmacol. 110, 36-42.
18. Keseberg, U., Schmidt, W.J., 1995. Low-dose challenge by the NMDA receptor antagonist dizocilpine exacerbates the spatial learning deficit in entorhinal cortex-lesioned rats. Behav. Brain Res. 67, 255-261.
19. Knabler, M.B., Rickler, K., 1995. Psychosis associated with felbamate treatment. J. Clin. Psychopharmacol. 15, 292-293.
20. Koek, W., Colpaert, F.C., 1990. Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: Relationship with phencyclidine-like behavioral effects. J. Pharmacol. Exp. Ther. 252, 349-357.
21. Kretschmer, B.D., 1994. Felbamate, an anti-convulsive drug, has anti-Parkinsonian potential in rats. Neurosci. Lett. 179, 115-118.
22. Kretschmer, B.D., Bubser, M., Schmidt, W.J., 1995. Behavioral and neurochemical actions of the strychnine-insensitive glycine receptor antagonist 7-chlorokynurenate in rats. Eur. J. Pharmacol. 280, 37-45.
23. Kretschmer, B.D., Koch, M., 1997. Role of the strychnine-insensitive glycine binding site in the nucleus accumbens and anterodorsal striatum in sensorimotor gating: A behavioral and microdialysis study. Psychopharmacology 130, 131-138.
24. Kretschmer, B.D., Schmidt, W.J., 1996. Behavioral effects mediated by the modulatory glycine site of the NMDA receptor in the anterodorsal striatum and nucleus accumbens. J. Neurosci. 16, 1561-1569.
25. Kretschmer, B.D., Winterscheid, B., Danysz, W., Schmidt, W.J., 1994. Glycine site antagonists abolish dopamine D2 but not D1 receptor mediated catalepsy in rats. J. Neural Transm. 95, 123-136.
26. Kretschmer, B.D., Zadow, B., Volz, T.L., Volz, L., Schmidt, W.J., 1992. The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior. J. Neural Transm. 87, 23-35.
27. Kristensen, J.D., Svensson, B., Gordh, T., 1992. The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up' pain after intrathecal administration in humans. Pain 51, 249-253.
28. Laurie, D.J., Seeburg, P.H., 1994. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur. J. Pharmacol. 268, 335-345.
29. Leppik, E.E., Dreifuss, F.E., Pledger, G.W., Graves, N.M., Santilli, N., Drury, I., Tsay, J.Y., Jocobs, M.P., Bertram, E., Cereghino, J.J., Cooper, G., Sahlroot, J.T., Sheridan, P., Ashworth, M., 1991. Felbamate for partial seizures. Neurology 41, 1785-1789.
30. Luby, E.D., Gottlieb, J.S., Cohen, B.D., Rosenbaum, G., Domino, E.F., 1962. Model psychoses and schizophrenia. Am. J. Psychiatry 119, 61-67.
31. Malhotra, A.K., Pinals, D.A., Weingartner, H., Sirocco, K., Missar, C.D., Pickar, D., Breier, A., 1996. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology 14, 301-307.
32. Mansbach, R.S., 1991. Effects of NMDA receptor ligands on sensorimotor gating in the rat. Eur. J. Pharmacol. 202, 61-66.
33. Matsumoto, R.R., Nguyen, D.C., Truong, D.D., 1995. Strychnine-insensitive glycine site antagonists attenuate a cardiac arrest-induced movement disorder. Eur. J. Pharmacol. 275, 117-123.
34. Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashey, N., Sakmann, B., Seeburg, P.H., 1992. Heteromeric NMDA receptors: Molecular and functional distinction of subtypes. Science 256, 1217-1221.
35. Muir, K.W., Grosset, D.G., Gamzu, E., Lees, K.R., 1994. Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br. J. Clin. Pharmacol. 38, 33-38.
36. Olney, J.W., Labruyere, J., Wang, G., Wozniak, D.F., Price, M.T., Sesma, M.A., 1991. NMDA antagonist neurotoxicity: Mechanism and prevention. Science 254, 1515-1518.
37. Rockstroh, S., Emre, M., Tarral, A., Pokorny, R., 1996. Effects of the novel NMDA receptor antagonist SDZ EAA 494 on memory and attention in humans. Psychopharmacology 124, 261-266.
38. Schmidt, W.J., 1986. Intrastriatal injection of DL-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapine. Psychopharmacology 90, 123-130.
39. Shapiro, M.L., Caramanos, Z., 1990. NMDA antagonist MK-801 impairs acquisition but not performance of spatial working and reference memory. Psychobiology 18, 231-243.
40. Singh, L., Menzies, R., Tricklebank, M.D., 1990. The discriminative stimulus properties of (+)-Ha-966, an antagonist at the glycine/ N-methyl-D-aspartate receptor. Eur. J. Pharmacol. 186, 129-132.
41. Smith, S.E., Meldrum, B.S., 1992. The glycine-site NMDA receptor antagonist, R-(+)-c/s-á-methyl-3-amino-1-hydroxypyrrolid-2-one, L-687,414 is anticonvulsant in baboons. Eur. J. Pharmacol. 211, 109-111.
42. Standaert, D.G., Testa, C.M., Young, A.B., Penny, J.B., 1994. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J. Comp. Neurol. 343, 1-16.
43. Sveinbjornsdottir, S., Sander, J.W., Upton, D., Thompson, P.J., Patsalos, P.N., Hirt, D., Emre, M., Lowe, D., Duncan, J.S., 1993. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. 16, 165-174.
44. Svensson, A., Pileblad, E., Carlsson, M., 1991. A comparison between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist D-CPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice. J. Neural Transm. 85, 117-159.
45. Tiedtke, P.I., Bischoff, C., Schmidt, W.J., 1990. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J. Neural Transm. 81, 173-182.
46. Tricklebank, M.D., Saywell, K., 1990. Behavioural properties of antagonists acting at the glycine modulatory site on the NMDA receptor/ion channel complex. Soc. Neurosci. Abstr. 16 (462), 200-201.
47. Troupin, A.S., Mendius, J.R., Cheng, F., Risinger, M.W., 1986. MK-801. Curr. Probl. Epilepsy 14, 191-201.
48. Trullas, R., Skolnick, P., 1990. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 185, 1-10.
49. Tsuchida, E., Bullock, R., 1995. The effect of the glycine site-specific N-methyl-D-aspartate antagonist ACEA 1021 on ischemic brain damage caused by acute subdural hematoma in the rat. J. Neurotrauma 12, 279-288.
50. Warner, D., Martin, D., Ludwig, P., McAllister, A., Keana, J., Weber, E., 1995. In vivo models of cerebral ischemia: Effects of parenterally administered NMDA receptor glycine site antagonists. J. Cereb. Blood Flow Metab. 15, 188-196.
51. Watanabe, M., Inoue, Y., Sakimura, K., Mishina, M., 1993. Distinct distributions of five N-methyl-D-aspartate receptor channel subunit mRNA's in the forebrain. J. Comp. Neurol. 338, 377-390.
52. Watanabe, Y., Himi, T., Saito, H., Abe, K., 1992. Involvement of glycine site associated with the NMDA receptor in hippocampal long-term potentiation and acquisition of spatial memory in rats. Brain Res. 582, 58-64.
53. Wiley, J.L., Cristello, A.F., Balster, R.L., 1995. Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice. Eur. J. Pharmacol. 294, 101-107.
54. Wood, E.R., Bussey, T.J., Phillips, A.G., 1992. A glycine antagonist reduces ischemia-induced CA1 cell loss in vivo. Neurosci. Lett. 145, 10-14.
55. Woodward, R.M., Huettner, J.E., Guastella, J., Keana, J.F.W., Weber, E., 1995. In vitro pharmacology of ACEA-1021 and ACEA-1031: Systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol. Pharmacol. 47, 568-581.